Home > Investment and Entrepreneurship> Key Projects

Huangpu to add another biomedical project

Updated : 2022-09-26

Thermo Fisher Scientific, the world's largest manufacturer of scientific analytical instruments and a global leader in enabling technological progress, announced that it will invest in the establishment of Thermo Fisher Scientific's Guangdong-Hong Kong-Macao Greater Bay Area Base in Huangpu on Sept 20.

The base is scheduled to be completed and put into production in 2023. It is expected to be constructed in the China-Singapore Guangzhou Knowledge City International Biomedical Innovation Center, covering an area of about 16,000 square meters.

After completion, the Guangdong-Hong Kong-Macao Greater Bay Area base will make full use of Thermo Fisher's cutting-edge technology advantages in the field of scientific services to produce high-value-added products, including high-end laboratory equipment, analytical instruments, and laboratory consumables.

Hann Pang, president of Thermo Fisher Scientific China, said that the Greater Bay Area is an important area that gathers China's biopharmaceutical industries, while Huangpu district has become a center for the development of the biomedical industry with global competitiveness and influence.

The base will adhere to the development strategy of taking root in China and serving China, further expanding the localization development layout of Thermo Fisher, as well as continuing to empower the construction of a regional industrial ecosystem.

Thermo Fisher Scientific is a global leader in enabling technological advancement, with annual sales of approximately $40 billion.

In the 40 years since Thermo Fisher Scientific entered China, it has nine factories that have been operating in Shanghai, Beijing, Suzhou, and Guangzhou, as well as five application development centers and demonstration laboratories that have been established nationwide.

In the future, Thermo Fisher Scientific will further team with Chinese partners to jointly help the vigorous development of China's life science and biomedical industries.

At present, Guangzhou's Huangpu district, as the core area for the development of Guangzhou's biopharmaceutical industry, has built a "two cities and one island" high-end development platform for Guangzhou International Bio Island, Guangzhou Science City, and China-Singapore Guangzhou Knowledge City, forming a complete industrial ecosystem chain covering research and development, pilot testing, as well as production. 

The settlement of Thermo Fisher Scientific's Guangdong-Hong Kong-Macao Greater Bay Area Base will further help the development of the biomedical industry in Huangpu district.

At present, Huangpu is home to more than 3,000 biopharmaceutical enterprises, covering the entire industrial chain of R&D, production, and sales in the fields of drugs, equipment, and reagents.

Copyright © Guangzhou Development District People's Government.
All rights reserved. Presented by China Daily